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Abstract
Background: In sub-Saharan Africa, acute respiratory infections (ARI), acute gastrointestinal infections (GI) and acute
febrile disease of unknown cause (AFDUC) have a large disease burden, especially among children, while respective
aetiologies often remain unresolved. The need for robust infectious disease surveillance to detect emerging
pathogens along with common human pathogens has been highlighted by the ongoing novel coronavirus disease
2019 (COVID-19) pandemic. The African Network for Improved Diagnostics, Epidemiology and Management of
Common Infectious Agents (ANDEMIA) is a sentinel surveillance study on the aetiology and clinical characteristics
of ARI, GI and AFDUC in sub-Saharan Africa.
Methods: ANDEMIA includes 12 urban and rural health care facilities in four African countries (Côte d’Ivoire, Burkina
Faso, Democratic Republic of the Congo and Republic of South Africa). It was piloted in 2018 in Côte d’Ivoire and the
initial phase will run from 2019 to 2021. Case definitions for ARI, GI and AFDUC were established, as well as syndrome-
specific sampling algorithms including the collection of blood, naso- and oropharyngeal swabs and stool. Samples are
tested using comprehensive diagnostic protocols, ranging from classic bacteriology and antimicrobial resistance
screening to multiplex real-time polymerase chain reaction (PCR) systems and High Throughput Sequencing. In March
2020, PCR testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and analysis of full genomic
information was included in the study. Standardised questionnaires collect relevant clinical, demographic, socio-
economic and behavioural data for epidemiologic analyses. Controls are enrolled over a 12-month period for a nested
case-control study. Data will be assessed descriptively and aetiologies will be evaluated using a latent class analysis
among cases. Among cases and controls, an integrated analytic approach using logistic regression and Bayesian
estimation will be employed to improve the assessment of aetiology and associated risk factors.
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Discussion: ANDEMIA aims to expand our understanding of ARI, GI and AFDUC aetiologies in sub-Saharan Africa using
a comprehensive laboratory diagnostics strategy. It will foster early detection of emerging threats and continued
monitoring of important common pathogens. The network collaboration will be strengthened and site diagnostic
capacities will be reinforced to improve quality management and patient care.
Keywords: Acute respiratory tract infections, Acute gastrointestinal infections, Acute febrile disease of unknown cause,
Sentinel surveillance, Sub-Saharan Africa, Aetiologies, Outbreak detection, Antimicrobial resistance, SARS-CoV-2, COVID-19
Background
Pneumonia, diarrhoea and fevers persist as frequent
reasons for seeking healthcare in low- and middle-
income countries, particularly among children [1–5].
Sub-Saharan Africa (SSA) bears a disproportionately
high burden of morbidity and mortality due to such
common infections [6–8]. While health interventions
like the introduction of the pneumococcal and
Haemophilus influenzae vaccines [9], or improvements
of sanitation have contributed to overall declines in
under-five mortality attributable to acute respiratory in-
fections (ARI), gastrointestinal infections (GI) and acute
febrile disease of unknown cause (AFDUC) since 1990
[10, 11], they remain among the top five causes of death
in sub-Saharan Africa [8]. The Global Enteric Multicen-
ter Study (GEMS) found that the six most frequent
pathogens causing GI in children less than 5 years in
African and Asian low- and middle-income countries
were Shigella spp., rotavirus, adenovirus, enterotoxigenic
Escherichia coli (ETEC), Cryptosporidium spp. and Cam-
pylobacter spp. [12]. The Pneumonia Etiology Research
for Child Health (PERCH) study also found that a small
set of pathogens accounted for most cases of severe
pneumonia in children requiring hospital admission in
sub-Saharan Africa and Asia, dominated by Streptococ-
cus pneumoniae, respiratory syncytial virus, human
metapneumovirus and rhinovirus [13].
Undifferentiated non-malarial fever makes up a signifi-
cant proportion of childhood disease burden in Africa
and Asia [14, 15]. AFDUC is often investigated in single
pathogen studies, e.g. on typhoid fever [16]. It is less
frequently assessed at the syndrome level, as it can have
a multitude of infectious causes and therefore requires
broad diagnostics [1, 17]. A recent systematic review
identified Staphylococcus aureus, non-typhoidal Salmon-
ella and Escherichia coli to be the most commonly
reported bacterial causes, and arboviruses to be among
the most common viral causes of AFDUC in SSA [5].
This review highlighted the lack of data from rural areas,
which tends to be neglected by surveillance efforts. In
addition, febrile illness often remains undiagnosed due
to the lack of broad routine laboratory testing. For
example, pathogens other than Plasmodium spp. were
found to cause febrile disease in children less than 5
years in nearly half of the investigated cases in Burkina
Faso, while in 24% of the cases, no causative agent was
detected [18]. Recently, the Febrile Illness Evaluation in
a Broad Range of Endemicities (FIEBRE) study was
established to investigate causes of febrile illness in three
SSA countries as well as two Asian countries [19].
The aforementioned evidence underscores the com-
plexity and interrelatedness of ARI, GI and AFDUC,
where symptoms and causative agents often overlap.
ARI and GI are associated with fevers, but these patients
are often only tested for common respiratory or gastro-
intestinal pathogens, leaving a proportion of aetiologies
unresolved. While large-scale surveillance programs have
investigated each syndrome on its own (e.g. the PERCH
study among those with severe pneumonia [13], the
GEMS study among those with GI [20] and the FIEBRE
study among those with febrile illness but excluding ARI
and GI cases [19]), simultaneous surveillance of all three
highly related disease syndromes, across ecosystems and
demographic settings, is still lacking to date. These
syndromes are often treated empirically due to limited
access to broad high-quality laboratory diagnostics,
which hinders informed treatment decisions and tar-
geted health interventions. A comprehensive surveillance
program could help address important knowledge gaps,
particularly in the understanding of AFDUC or of other
threats such as antimicrobial resistance (AMR). Further-
more, it can function as an early warning system for
infectious disease outbreaks, such as the COVID-19
pandemic [21]. By including acute respiratory infection,
the system can provide a platform for monitoring and
researching the disease dynamics of SARS-CoV-2, which
is currently spreading in SSA [22].
The African Network for Improved Diagnostics,
Epidemiology and Management of Common Infectious
Agents (ANDEMIA) is a transnational sentinel surveil-
lance study on the aetiology and clinical characteristics
of ARI, GI and AFDUC in SSA. Sites are established in
Burkina Faso (BF), Côte d’Ivoire (CIV), the Democratic
Republic of the Congo (DRC) and the Republic of South
Africa (RSA), countries which carry a significant burden
of ARI, GI and AFDUC [8]. In an effort to fully elucidate
the extent of the disease burden, ANDEMIA is inclusive
of all age groups and will not limit its research to easy-
access hospital sites but also include rural regions.
Especially in regions with high biodiversity and close
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human-animal contact, zoonotic pathogens are at the
source of emerging infections, which may be related to
causes of AFDUC, ARI and GI as well [23]. ANDEMIA
aims to improve clinical microbiological practice, imple-
ment advanced molecular diagnostics, and collect broad




The overall aims of the ANDEMIA surveillance study
are to build capacities and strengthen the network
collaboration to enable the enhanced detection, control,
treatment and prevention of ARI (including COVID-19),
GI and AFDUC as well as the spread of AMR in SSA.
Specifically, the study will:
1) identify the aetiologies found in cases of ARI, GI,
and AFDUC syndromes using large pathogen test
panels;
2) assess the associated clinical, demographic and
socio-economic characteristics and behavioural
factors;
3) determine the antibiotic resistance profiles of
relevant bacteria; and.
4) investigate the molecular epidemiology of relevant
etiological agents.
ANDEMIA aims to use surveillance data for develop-
ing targeted interventions, assessing their effectiveness
and informing further in-depth investigations. Our
assumption is that locally-adapted interventions based
on broad integrated clinical, epidemiological and labora-
tory surveillance data will more effectively improve
patient outcomes and disease prevention efforts than
vertical disease programs. Moreover, we will also put
focus on a ‘One Health’ approach to further explore
pathogen emergence and the intersection of human and
animal health including aspects such as antibiotic use
and exposure to zoonotic pathogens. Since the surveil-
lance study was established before the COVID-19 pan-
demic emerged, ANDEMIA also presents a valuable
opportunity to compare data from before and through-
out the course of the pandemic to detect SARS-CoV-2
trends and identify risk factors for infection, disease se-
verity, co-infections, as well as the molecular dynamics
of the virus through High Throughput Sequencing.
Study design and sentinel sites
ANDEMIA is a prospective syndromic hospital-based
sentinel surveillance study at 12 hospital sentinel sites
(Fig. 1) in the African countries BF, CIV, DRC and RSA.
After a pilot phase in 2018 at CIV, it will initially run
from 2019 to 2021 and then be evaluated. CIV and DRC
have two urban and two rural sentinel sites whereas
RSA and BF have one urban and one rural sentinel site
each, which are situated in different climatic and bio-
diversity settings. Urban sites are characterized by higher
population density and mobility and access to acute care
hospitals. Rural sites are characterized by lower
Fig. 1 ANDEMIA study sites. Legend: CHR, Centre Hospitalier Regional; CHU, Centre Hospitalier et Universitaire; CS, Centre de Santé; CSU, Centre
de Santé Urbain; CMA, Centre Médical avec Antenne chirurgicale; HGR, Hospital General Regional. Map taken from NASA, Public domain
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population density and mobility, where patients attend
smaller health centres and have closer contact to wildlife
and/or livestock. The rationale behind this surveillance
study design is that exposure to e.g. zoonotic pathogens
or globally circulating microorganisms including anti-
microbial resistant pathogens is expected to vary be-
tween the sentinel sites (Fig. 2). Including a range of
sites will allow us to better investigate the effect of cli-
mate, biodiversity and demography on human health in
a ‘One Health’ framework.
Sentinel surveillance is coordinated by each country’s
partner institutions, i.e. the Centre Hospitalier Universitaire
(CHU) Bouaké and the Laboratoire National d’Appui au
Développement Agricole / Laboratoire Central de
Pathologie Animale (LANADA) in CIV, the Centre
Muraz and the CHU de Sourô Sanou in BF, the Institut
National de la Recherche Biomédicale (INRB) and the
Hôpital Universitaire/Université de Kinshasa in DRC and
the National Institute for Communicable Diseases (NICD)
and University of Pretoria in RSA. Technical support
according to needs identified by partners and advanced
epidemiological and laboratory analyses are provided by
the Robert Koch-Institute in Germany. Figure 1 displays
demographic characteristics of all sites. The program is
coordinated by the CHU Bouaké, CIV, and the Robert
Koch-Institute (RKI, Germany).
Study participants and sample size
The study population includes patients of all ages that
present to the sentinel sites, who meet the ARI, GI or
AFDUC case definitions and provide informed consent.
Case definitions was based on published surveillance stan-
dards [ARI: [24], GI: [25], AFDUC: [26, 27]] and network
expert consensus (Fig. 3). Patients are enrolled either as
ARI (including suspected COVID-19 disease), GI or
AFDUC cases alone, or as cases with both ARI and GI.
Exclusion criteria include:
1) for AFDUC patients: being malaria-positive and not
yet 48 h under malaria therapy; therefore, malaria
testing is conducted (rapid test or blood smear) and
data are recorded for all AFDUC patients presenting
with a fever ≥38 °C;
2) new-borns who have not been discharged following
delivery; and.
3) patients transferred directly to intensive care
units without passing through the admission
ward.
The planned sample size is 320 patients per syndrome
per year per site. As such, the study is expected to pro-
vide sufficient power to detect aetiologies and pathogens
of interest. The sample size calculation was based on a
two-sided test, 5% significance level, 80% power, and an
expected aetiology of 10% based on previous literature
from respiratory disease surveillance in SSA (e.g. influ-
enza virus) [28]. This target sample size may be more
difficult to meet in rural sites if fewer patient admissions
are seen. Sensitivity analyses will be run to evaluate the
ongoing results and observed margins of error.
Fig. 2 ANDEMIA study design. Sentinel hospital sites are located along gradients from rural to urban, as well as dry to tropical climate to account
for the various effects that demography, climate and biodiversity may have on local pathogen compositions. Image edited with Adobe
Photoshop CS6
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Enrolment, informed consent and questionnaire
Patients meeting case definitions are identified by
surveillance officers or medical staff trained in the
ANDEMIA protocol upon presentation at the hospital.
Surveillance officers discuss the study with the identified
patients and provide them with a study information
sheet explaining the objectives of the surveillance study,
the benefits of participation and potential risks. If they
agree to participate in the surveillance study, they are
asked to sign standardised informed consent forms.
Using a standardized structured case investigation form,
surveillance officers collect clinical, demographic, socio-
economic and behavioural data (Table 1). Further ethical
considerations are detailed in the ‘Declarations’ section.
Sampling procedures
Specimens are collected right after questionnaire
completion by study staff and respective sampling
forms are completed. Whole blood specimens are col-
lected in bacterial culture bottles as well as Ethylene-
diaminetetraacetic acid (EDTA) tubes. Clotted blood
tubes for subsequent serological analyses are collected
from adult febrile patients. Among ARI patients,
naso- and oropharyngeal swabs are collected and
stored in universal transport media (UTM). Among
GI patients, stool specimens or rectal wipes or swabs
are collected. In addition, an aliquot of cerebrospinal
fluid (CSF) will be included if a respective specimen
is requested for routine diagnostics by the treating
physician.
Nested case-control study
One set of healthy controls will also be enrolled as part
of the surveillance study. The nested case-control study
will enable the further investigation of aetiologies of
active infection versus colonization and the association
Fig. 3 Case definitions decision tree. Legend: *respiratory symptoms are cough, expectoration, dyspnoea, pulmonary consolidation, chest pain;
**other than acute neurological disease or arbovirosis, evident causes are soft tissue infection (including dental abscess, severe gum or mouth
infection) or muscle infection, severe surgical condition or surgical abdomen, kidney or urinary tract infection, HIV Opportunistic Diseases (WHO,
2010b) and Acute Retroviral Syndrome. ARI, acute respiratory infection; AFDUC, acute febrile disease of unknown cause; GI, acute
gastrointestinal infection
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between infection outcomes and risk factors. Controls
will receive the study information sheet and consent to
study participation by signing a consent form. Each
country is similarly expected to enrol 320 controls over
a 12-month period in order to capture seasonal vari-
ation, and controls will be split to match frequency of
case enrolment 1:1 at the sentinel sites. Controls will be
frequency-matched by age group (infants < 1 year of age;
young children 1–4 years of age; children 5–17 years
of age; adults 18–44 years of age; older adults > 44
years of age).
Ongoing sensitivity analyses will assess the power to
detect significant differences between proportions of cases
and controls for which a specific pathogen is found.
Inclusion criteria for controls are: 1) no symptoms of GI
infection (including diarrhoea, vomiting), ARI (including
cough, expectoration, pulmonary consolidation, chest
pain, pneumonia, apnoea) or fever, rash, arthralgia, and
signs or symptoms of neurological disease in the previous
3 weeks; and 2) providing informed consent. Exclusion
criteria for controls are: 1) being a family member or care-
giver of an ANDEMIA case; 2) admitted to the hospital
for longer than 48 h; 3) being pregnant; 4) use of antibi-
otics in the past 24 h; and 5) previously enrolled as an
ANDEMIA case or control. The case investigation form
will be completed, and sampling as well as laboratory
analyses will be equivalent to ANDEMIA patients with the
exclusion of bacterial culturing (Table 2).
Laboratory testing and quality management
Main laboratory approaches are summarized in Table 2.
After an initial culturing, positive whole blood and stool
specimens are sub-cultured onto the appropriate
selective and non-selective media and examined for the
presence of respiratory, fever-associated and enteric
pathogens. Microorganism identification and antimicro-
bial susceptibility testing will be performed at the part-
ners’ laboratories following standardized protocols.
Bacterial isolates are stored on site at − 80 °C for further
molecular characterization.
Among ARI cases, a real-time multiplex polymerase
chain reaction (PCR; FTD® Bacterial pneumonia CAP; Fast
Track Diagnostics Luxembourg) is performed on nucleic-
acid extracted from whole blood specimens to detect the
following respiratory bacteria: Streptococcus pneumoniae,
Staphylococcus aureus, Haemophilus influenzae, Moraxella
catarrhalis, Legionella pneumophila/ Legionella longbea-
chae, Mycoplasma pneumoniae and Chlamydia pneumo-
niae. Naso- and oropharyngeal swabs are tested using
multiplex real-time PCR testing for respiratory viruses and
bacteria (FTD® respiratory pathogens 33; Fast Track
Diagnostics Luxembourg). The assay targets influenza A,
influenza B, influenza C, influenza A (H1N1) viruses,




Clinical Physical examination data












Living conditions/water and sanitation
Exposure to animals and animal products
Travel history
One-month follow-up Disease outcome (recovered/ongoing
symptoms/deceased)
Legend: ARI acute respiratory infection; AFDUC acute febrile disease of
unknown cause; GI acute gastrointestinal infection
Table 2 Biological sampling and laboratory tests conducted in the ANDEMIA study
Biological samples Study population Laboratory testing
Whole blood Febrile cases Blood culture
Cases/ healthy controls Molecular detection of bacteria (FTD® Bacterial pneumonia CAP) for RTI cases
Cases/ healthy controls Molecular detection of viruses and bacteria (multiplex PCR-based macroarray assay)
for AFDUC cases and RTI/GI cases without first-line pathogen detection
Naso−/ Oropharyngeal swabs Cases/ healthy controls Molecular detection of viruses and bacteria (FTD® respiratory pathogens 33)
Cases Molecular detection of SARS-CoV-2 (TIB Molbiol LightMix® SarbecoV E-gene and
SARS-CoV-2 RdRP-gene) from March 2020 onwards, and retrospectively from
December 2019 on
Stool Cases Stool culture
Cases/ healthy controls Molecular detection of viruses (FTD® viral gastroenteritis), bacteria (FTD® bacterial
gastroenteritis) and parasites (FTD® stool parasites)
Legend: ARI acute respiratory infection; GI acute gastrointestinal infection; AFDUC acute febrile disease of unknown cause
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parainfluenza viruses 1, 2, 3 and 4, coronaviruses NL63,
229E, OC43 and HKU1, human metapneumoviruses A and
B, rhinovirus, respiratory syncytial viruses A and B, adeno-
virus, enterovirus, parechovirus, bocavirus, Pneumocystis
jirovecii, Mycoplasma pneumoniae, Chlamydia pneumo-
niae, Streptococcus pneumoniae, Haemophilus influenzae
type B, Staphylococcus aureus, Moraxella catarrhalis,
Bordetella spp. (except Bordetella parapertussis), Klebsiella
pneumoniae, Legionella pneumophila/Legionella longbea-
chae, Salmonella spp. and Haemophilus influenzae. Real-
time RT-PCR detection of SARS-CoV-2 (TIB Molbiol
LightMix® SarbecoV E-gene and TIB Molbiol LightMix®
SARS-CoV-2 RdRP) was implemented since March 2020
on extracted nucleic acids from respiratory specimens.
Samples from November 2019 on were retrospectively
tested as well [29].
Among GI patients, three real-time multiplex PCR sys-
tems are used on stool specimens to detect the following
pathogens: the enteric viruses norovirus GI, norovirus II,
human astrovirus, rotavirus, human adenovirus and
sapovirus (FTD viral gastroenteritis, Fast Track Diagnos-
tics Luxembourg), the enteric bacteria Campylobacter
coli/jejuni /lari, Clostridioides difficile, Escherichia coli
verotoxin positives, Salmonella spp., Shigella spp., enter-
oinvasive Escherichia coli and Yersinia enterocolitica
(FTD bacterial gastroenteritis), and lastly the enteric
parasites Entamoeba histolytica, Cryptosporidium spp.
and Giardia lamblia (FTD stool parasites). Rotavirus-
positive specimens will be genotyped using standardized
methods and primers specific for G1, G2, G3, G4, G8,
G9, G10, G12 and for P[4], P[6], P[8], P[9], P[10], P[11]
and P[14] strains.
Among AFDUC patients, a multiplex PCR-based
macroarray assay (Fever Chip) will be used on whole
blood and CSF specimens for differential diagnosis of 30
pathogens associated with febrile disease, haemorrhagic
fever disease and meningo-encephalitis including both
common and less frequently encountered viruses, bac-
teria, parasites, and arboviruses of medical importance
in SSA [30]. Pathogens included on the Fever Chip are
Crimean-Congo haemorrhagic fever virus, Rift Valley
Fever virus, West Nile virus, Chikungunya virus, Dengue
virus, Sindbis virus, Rubella virus, Cytomegalovirus,
Measles virus, Mumps virus, Herpes simplex 1 and 2
viruses, Varicella Zoster virus, Rabies virus, Epstein-Barr
virus, JC virus, Enterovirus, Adenovirus, Flavivirus
family, Hepatitis A and B viruses, Rickettsia spp., Borre-
lia burgdorferi/garinii, Brucella spp., Coxiella burnetti,
Leptospira spp. Mycobacterium tuberculosis, Ehrlichia
spp., Neisseria meningitidis and Plasmodium spp. The
short viremia for certain arboviruses may necessitate the
additional use of serological tests, e.g. for the Alphavirus
and Flavivirus genera. In positive cases, neutralization
tests will be used to differentiate between virus species
in the Alphavirus (Sindbis virus; Chikungunya virus,
Middelburg virus, Semliki Forest virus and O’nyong-
nyong virus) and Flavivirus (Yellow Fever virus, Dengue
virus, West Nile virus) genera. Moreover, the sera collec-
tion will allow the investigation of the seroprevalence of
emerging viruses like SARS-CoV-2 over time. Among
ARI and GI patients presenting with a fever, and for
which test results are negative for respectively all re-
spiratory and gastrointestinal pathogens, whole blood
samples will also be analysed with the Fever chip.
A subset of positive specimens (dependent on the path-
ogens found, e.g. specimens positive for human metap-
neumoviruses, respiratory syncytial viruses, enteroviruses)
will be further sequenced by High Throughput Sequen-
cing (HTS) methodology (amplicon-based enrichment,
hybridization capture or shotgun sequencing when rele-
vant) in order to generate full length genomic data for
subsequent analyses. Specimens tested positive for SARS-
CoV-2 by real time PCR will be sequenced on-site via an
amplicon-based full genome sequencing approach [31]
using Oxford Nanopore Technology (ONT) devices.
Nucleic acid sequences will be provided to the scientific
community through respective data repositories.
Most bacteriological and molecular analyses are con-
ducted at national partner laboratories and respective
staff are trained extensively (e.g. through multiple work-
shops and regular follow-up and discussion of data qual-
ity) in the use of relevant techniques. Standard operating
procedures of laboratory assays are harmonized among
participating laboratories. In addition to using standard-
ized assays, reference strains are used in bacteriological
analyses and quality control. Protocols for antimicrobial
susceptibility testing were developed based on the
European Committee on Antimicrobial Susceptibility
Testing guidelines [32]. For quality monitoring of mo-
lecular testing, a blinded PCR control panel of positive
and negative control specimen will be provided to all
partner laboratories. For biological specimens, adherence
to guidelines for recommended temperature and pro-
cessing times (i.e., storage of specimens for maximum 2
h at ambient temperature or for maximum 12 h at 4 °C,
immediate storage at − 80 °C after aliquoting) were
implemented through standard guidelines. In case of
irregularities, sentinel sites will enter the details on the
concerned specimen in the database and post hoc re-
evaluation/repetitions of respective laboratory testing
will be conducted. All laboratory results are recorded in
respective laboratory results forms.
Patient follow-up
A follow-up interview will be conducted by trained
surveillance staff via telephone to determine disease
outcome of patients after 1 month, i.e. patient recovery,
ongoing disease symptoms, and subsequent hospital
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stays. Patients complete a respective one-month follow-
up questionnaire.
Data management and quality control
All data collection and analyses are conducted according
to standard operating procedures. All study forms (e.g.
case investigation form, one-month follow-up form,
sampling form, laboratory results forms) were translated
and validated in French for CIV, BF and DRC and English
for RSA. Paper data collection forms are completed on site
at the point of care and then entered by trained data clerks
into a customized database specific for ANDEMIA includ-
ing a range of plausibility checks to avoid data entry errors
and missing data. Visual data validation of data entered is
done by a second person and marked as validated. Regular
data management reports are sent to sites for validation
and correction of data as needed. Regular trainings on the
use of the database and data management for ANDEMIA
are conducted at the site and country level. All current
study form versions are made available to ANDEMIA staff
on the database platform.
Analysis plan
Disease aetiologies and patient characteristics will be
descriptively summarized by those with ARI, GI and
AFDUC. A latent class analysis integrating the multiple
test results among cases only will be conducted to fur-
ther evaluate aetiology. Among the cases and controls,
the distribution of aetiologies will be compared using lo-
gistic regression to estimate corresponding odds ratios.
Expanding on the odds ratio approach, recent novel ap-
proaches using Bayesian estimation including elements
of attributable fraction and latent class analyses will be
explored in order to better integrate multiple types of
measurements, correct for test performance, and accom-
modate a larger number of pathogens. Patient clinical,
demographic, socio-economic and behavioural risk fac-
tors will be assessed using conditional logistic regression
analysis. Trend analyses such as time series methods will
be used to determine if there is a seasonal pattern of cer-
tain pathogens, e.g. respiratory viruses. These analyses
will be conducted with R and STATA.
A series of pathogen-specific molecular epidemio-
logical and phylogenetic studies will also be conducted
for pathogens of global importance, e.g. respiratory vi-
ruses including SARS-CoV-2. Here, HTS approaches will
be used in order to generate full genome datasets. Gen-
omic HTS data will be analysed in maximum-likelihood
as well as Bayesian frameworks [33, 34] in order to infer
on divergence times and geographic origins of pathogen
lineages. For SARS-CoV-2 sequence generation and ana-
lysis, protocols provided by the ARTIC network will be
used [35], and virus lineages will be assigned using the
Pangolin nomenclature [36].
Discussion
The ANDEMIA network aims to establish sentinel sur-
veillance of ARI, GI and AFDUC given their high disease
burden worldwide. While studies on those diseases exist,
the novelty of ANDEMIA lies in its comprehensive diag-
nostic approach of all three highly interrelated disease
syndromes. This way, ANDEMIA expects to address
knowledge gaps regarding the aetiologies of those dis-
ease syndromes. The data generated here will build on
findings from other studies like the Global Approach to
Biology Research, Infectious diseases and Epidemics in
Low-income countries (GABRIEL) network, the PERCH
study on childhood pneumonia aetiology in the
Americas, Africa and Asia [37, 38] and the GEMS study
on causes of diarrhoea in children in Africa and Asia
[12, 39], where similar molecular diagnostic panels were
used. However, the inclusion of diverse study sites in dif-
ferent climatic, demographic and biodiversity settings
will further allow for the comprehensive investigation of
the interplay between circulating pathogens and related
factors in humans, including zoonotic pathogens from
wildlife and livestock.
ANDEMIA contributes to a better understanding of
global infectious disease dynamics and supports the
rapid detection and monitoring of outbreaks, as demon-
strated by its ability to easily include SARS-CoV-2 in the
existing sampling and testing strategy of respiratory
specimens. It now offers the possibility to investigate
SARS-CoV-2 dynamics in the past months and prospect-
ively. This illustrates the potential and flexibility of such
long-term disease surveillance studies. The study also
reinforces routine laboratory testing to build diagnostic
capacity of treatable disease at all hospital sites, such as
bacterial culture methods and AMR testing. Further-
more, it fosters South-South collaboration among
individuals and institutions in the selected Francophone
and Anglophone African countries, which also leads to a
more sustainable impact. ANDEMIA intends to use the
surveillance data to develop targeted interventions,
assess their effectiveness and consider other in-depth in-
vestigation studies. Data will be fed back into national
health information systems to facilitate translation of
findings into practice.
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